Your session is about to expire
← Back to Search
Procedure
Intervention for Pancreatic Cancer (EPIC-1 Trial)
Phase 2
Waitlist Available
Led By Morten Ladekarl, DMSc
Research Sponsored by Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 days and 52 days after treatment start
Awards & highlights
Summary
The study is investigating the efficacy and safety of combined irreversible electroporation (IRE) and checkpoint inhibition in metastatic pancreatic cancer.
Eligible Conditions
- Pancreatic Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 days, 11 days, 52 days after treatment start
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 days, 11 days, 52 days after treatment start
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Objective response rate (ORR) according to RECIST 1.1
Serious adverse reaction (SAR) rate according to CTCAE v5
Secondary study objectives
Adverse event rate (CTCAEv5, all grades)
Clinical benefit ratio
Leukocytes
+17 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment2 Interventions
Day 1: Pembrolizumab 400mg Day 10: Irreversible electroporation Day 42/84/126/168: Pembrolizumab 400mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~2850
Irreversible electroporation
2019
Completed Phase 3
~120
Find a Location
Who is running the clinical trial?
Odense University HospitalOTHER
776 Previous Clinical Trials
1,179,797 Total Patients Enrolled
Aalborg UniversityOTHER
281 Previous Clinical Trials
2,468,214 Total Patients Enrolled
Danish Cancer SocietyOTHER
149 Previous Clinical Trials
1,556,487 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger